Indication: For treatment of the symptoms of idiopathic Parkinson's disease (paralysis agitans), post-encephalitic parkinsonism
Pharmacology: Carbidopa, a noncompetitive decarboxylase inhibitor, is used in combination with levodopa for the treatment of Parkinson's disease.
Mechanism Of Action: When mixed with levodopa, carbidopa inhibits the peripheral conversion of levodopa to dopamine and the decarboxylation of oxitriptan to serotonin by aromatic L-amino acid decarboxylase. This results in increased amount of levodopa and oxitriptan available for transport to the CNS. Carbidopa also inhibits the metabolism of levodopa in the GI tract, thus, increasing the bioavailability of levodopa.
Drug Category: Dopamine Agents; Antiparkinson Agents; Antidyskinetics; ATC:N04BA
Absorption: rapidly decarboxylated to dopamine in extracerebral tissues so that only a small portion of a given dose is transported unchanged to the central nervous system.
Interactions:
DrugBank: Interactions for Carbidopa
Interactions for Carbidopa:
Caution should be exercised when the following drugs are administered concomitantly with LODOSYN (Carbidopa) given
with levodopa or carbidopa-levodopa combination products.
Symptomatic postural hypotension has occurred when LODOSYN, given with levodopa or carbidopa-levodopa combination
products, was added to the treatment of a patient receiving antihypertensive drugs. Therefore, when therapy with
LODOSYN, given with or without levodopa or carbidopa-levodopa combination products, is started, dosage adjustment of
the antihypertensive drug may be required.
There have been rare reports of adverse reactions, including hypertension and dyskinesia, resulting from the
concomitant use of tricyclic antidepressants and carbidopa-levodopa preparations.
Dopamine D2 receptor antagonists (e.g., phenothiazines, butyrophenones, risperidone) and isoniazid may
reduce the therapeutic effects of levodopa. In addition, the beneficial effects of levodopa in Parkinson's disease
have been reported to be reversed by phenytoin and papaverine. Patients taking these drugs with LODOSYN and levodopa
or carbidopa-levodopa combination products should be carefully observed for loss of therapeutic response.
Iron salts may reduce the bioavailability of carbidopa and levodopa. The clinical relevance is unclear.
Although metoclopramide may increase the bioavailability of levodopa by increasing gastric emptying,
metoclopramide may also adversely affect disease control by its dopamine receptor antagonistic properties.
Chemical IUPAC Name: 3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methyl-propanoicacid
Chemical Formula: C10H14N2O4
Half Life: 1-2 hours
Drug Type: Approved Drug
# Accession No: APRD00160
CAS Registry Number: 28860-95-9
Carbidopa News (When available)
Orion Oyj: Orion group 2005 financial statements09 Feb 2006 ...together with Novartis, launched a follow-up development, Stalevo®, which combines the standard treatment levodopa with entacapone and carbidopa, the two ... - Kauppalehti (press release),
Mylan Reports Third Quarter Adjusted Diluted EPS of $0.25Feb 2, 2006 Continued competition on certain products, primarily omeprazole, carbidopa/levodopa and Amnesteem(TM), was responsible for the overall unfavorable pricing and ... - MSN Money
International Approvals: Tasmar, Amplimexon, IV RemodulinJan 17, 2006 ...and reversible catechol-O-methyltransferase (COMT) inhibitor is indicated for use in combination with levodopa/benserazide or levodopa/carbidopa in patients ... - Medscape (subscription)
One day at a time with Parkinson'sJan 10, 2006 ...developing a cure. Today, the most widely prescribed treatment is a combination of two drugs, Levodopa and Carbidopa. They are described ... - Globe and Mail,
IMPAX Settles Patent Suit and Signs Marketing and Promotion ...Jan 19, 2006 ...target market for Carbatrol of approximately 8,300 neurologists in the US overlaps with the Company's target market for Vadova(TM) (carbidopa and levodopa). ... - Genetic Engineering News,
‘Time not right for stem cell experiment in Parkinson’s’15 Jan 2006 Peninsula On-line, ...admitted. "The most effective drug and cheapest treatment for Parkinson's Disease remains L-Dopa, which has been around for 40 years. ...
L-dopa therapy, other Parkinson’s optionsJan 10, 2006 Newsday, I believe my father has Parkinson's disease, and from what I've read, he only has a few years left. Might L-dopa therapy make a difference? ...
Is sleeping sickness linked to Spanish flu of 1918?Jan 2, 2006 Toronto Star, In 1969, Sacks administered the miracle awakening drug, laevo-dihydroxyphenylalanine, or L-DOPA, to his post-encephalitic patients. ...
Drug therapy no cure-all for Parkinson’sJan 8, 2006 Fort Wayne Journal Gazette, ...he only has a few years left. Might L-dopa therapy make a difference? – Marietta, Ga. Answer: I would first recommend that your ...
Fox Foundation Grant Funds Major Gene Therapy Advance For ...Jan 8, 2006 Medical News Today (press release), Current treatment options focus on replacing lost dopamine with the drug levodopa (L-dopa), which converts to dopamine in the brain, or brain surgery to ...
Suicide is PainlessDec 21, 2005 Maisonnueve, Like the sudden, brief clarity exhibited by coma patients on L-DOPA, George believes he may have escaped ruin—but, in fact, he’s still in a position where ...
Doug Dugal column: Bio-refining is the new buzz wordDec 18, 2005 Appleton Post Crescent, ...energy from the destructive distillation of wood; alcohol and yeast for fodder from sulfite pulping liquors; vanilla; glucose; medicine like L-dopa, from other ...
Home
Copyright phasechange.org 2006.
All Rights Reserved.
